• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Amyloid-beta (Aβ)-targeting monoclonal antibody trials in early Alzheimer's disease-Clinical outcome with gantenerumab.

作者信息

Xiao Bin, Tan Eng-King

机构信息

Department of Neurology, National Neuroscience Institute, Singapore, Singapore.

Neuroscience Academic Clinical Program, Duke-NUS Medical School, Singapore, Singapore.

出版信息

Clin Transl Med. 2024 Jan;14(1):e1559. doi: 10.1002/ctm2.1559.

DOI:10.1002/ctm2.1559
PMID:38279873
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10819083/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9ff/10819083/6dc8a2a3a413/CTM2-14-e1559-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9ff/10819083/6dc8a2a3a413/CTM2-14-e1559-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9ff/10819083/6dc8a2a3a413/CTM2-14-e1559-g001.jpg

相似文献

1
Amyloid-beta (Aβ)-targeting monoclonal antibody trials in early Alzheimer's disease-Clinical outcome with gantenerumab.早期阿尔茨海默病中靶向淀粉样β蛋白（Aβ）的单克隆抗体试验——甘特奈单抗的临床结果
Clin Transl Med. 2024 Jan;14(1):e1559. doi: 10.1002/ctm2.1559.
2
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.两项早期阿尔茨海默病甘特纳单抗的 3 期临床试验。
N Engl J Med. 2023 Nov 16;389(20):1862-1876. doi: 10.1056/NEJMoa2304430.
3
At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact.照料者为早期阿尔茨海默病患者在家中进行甘特钠单抗给药：可行性、安全性和药效学影响。
J Prev Alzheimers Dis. 2024;11(3):537-548. doi: 10.14283/jpad.2024.60.
4
Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?用于治疗阿尔茨海默病的淀粉样蛋白导向单克隆抗体：是否已到不可逆转的地步？
Expert Opin Biol Ther. 2014 Oct;14(10):1465-76. doi: 10.1517/14712598.2014.935332. Epub 2014 Jun 30.
5
What the Gantenerumab Trials Teach Us about Alzheimer's Treatment.甘特奈单抗试验对阿尔茨海默病治疗的启示
N Engl J Med. 2023 Nov 16;389(20):1918-1920. doi: 10.1056/NEJMe2310903.
6
Immunotherapy in Alzheimer's disease: focusing on the efficacy of gantenerumab on amyloid-β clearance and cognitive decline.阿尔茨海默病的免疫疗法：关注甘露特纳单抗对淀粉样蛋白-β清除和认知下降的疗效。
J Pharm Pharmacol. 2024 Sep 3;76(9):1115-1131. doi: 10.1093/jpp/rgae066.
7
The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset.索拉珠单抗和甘特珠单抗在预防因遗传突变导致早发性阿尔茨海默病的人群中预防阿尔茨海默病的潜力。
Expert Opin Biol Ther. 2018 Jan;18(1):25-35. doi: 10.1080/14712598.2018.1389885. Epub 2017 Oct 16.
8
Gantenerumab for the treatment of Alzheimer's disease.甘露特纳单抗治疗阿尔茨海默病。
Expert Opin Biol Ther. 2012 Aug;12(8):1077-86. doi: 10.1517/14712598.2012.688022. Epub 2012 May 15.
9
Profile of gantenerumab and its potential in the treatment of Alzheimer's disease.甘特奈单抗概况及其在阿尔茨海默病治疗中的潜力。
Drug Des Devel Ther. 2013 Nov 13;7:1359-64. doi: 10.2147/DDDT.S53401. eCollection 2013.
10
Structural aspects of Alzheimer's disease immunotherapy targeted against amyloid-beta peptide.针对淀粉样β肽的阿尔茨海默病免疫疗法的结构方面
Bratisl Lek Listy. 2018;119(4):201-204. doi: 10.4149/BLL_2018_037.

引用本文的文献

1
From Better Diagnostics to Earlier Treatment: The Rapidly Evolving Alzheimer's Disease Landscape.从更好的诊断到更早的治疗：快速演变的阿尔茨海默病格局
Medicina (Kaunas). 2025 Aug 14;61(8):1462. doi: 10.3390/medicina61081462.
2
Axonal Degeneration Across the Alzheimer's Disease Spectrum: A Longitudinal MRI and Fluid Biomarker Study.阿尔茨海默病谱系中的轴突退变：一项纵向MRI和血液生物标志物研究
medRxiv. 2025 Aug 15:2025.08.13.25333630. doi: 10.1101/2025.08.13.25333630.

本文引用的文献

1
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.两项早期阿尔茨海默病甘特纳单抗的 3 期临床试验。
N Engl J Med. 2023 Nov 16;389(20):1862-1876. doi: 10.1056/NEJMoa2304430.
2
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.多奈哌齐治疗早期症状性阿尔茨海默病的随机临床试验。
JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239.
3
Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke.一名接受lecanemab治疗并因中风接受t-PA治疗的患者发生多处脑出血。
N Engl J Med. 2023 Feb 2;388(5):478-479. doi: 10.1056/NEJMc2215148. Epub 2023 Jan 4.
4
Insights into the Pathophysiology of Alzheimer's Disease and Potential Therapeutic Targets: A Current Perspective.阿尔茨海默病的病理生理学洞察与潜在治疗靶点：当前视角
J Alzheimers Dis. 2023;91(2):507-530. doi: 10.3233/JAD-220666.
5
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
6
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.两项早期阿尔茨海默病中阿杜卡努单抗的随机 3 期研究。
J Prev Alzheimers Dis. 2022;9(2):197-210. doi: 10.14283/jpad.2022.30.
7
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics.阿尔茨海默病中的淀粉样蛋白假说：新疗法的新见解。
Nat Rev Drug Discov. 2022 Apr;21(4):306-318. doi: 10.1038/s41573-022-00391-w. Epub 2022 Feb 17.